US-based Entelos Inc develops predictive biosimulation models, which can be used instead of animals to test drugs. Clinical testing can be done from inception to the point where there is a product. Pfizer is a shareholder and other users of the models include Lilly, Johnson & Johnson and Unilever. It can be used for drugs and consumer products. It is estimated that Entelos' technology could cut the cost of developing a drug by $125m. Entelos joined Aim on 12 April 2006, when it raised £11.4m at 82.75p.